|
|
| | PROTAC RIPK degrader-2 Basic information |
| Product Name: | PROTAC RIPK degrader-2 | | Synonyms: | PROTAC RIPK degrader-2;PROTAC_RIPK2;PROTAC_RIPK2 2-(2-(2-(2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinolin-7-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl ((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)carbamate;PROTACRIPKdegrader-2/PROTAC_RIPK2;(2S,4R)-1-[(2S)-2-[14-({4-[(1,3-benzothiazol-5-yl)amino]-6-(2-methylpropane-2-sulfonyl)quinolin-7-yl}oxy)-3,6,9,12-tetraoxatetradecanamido]-3,3-dimethylbutanoyl]-4-hydroxy-N-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}pyrrolidine-2-carboxamide | | CAS: | 1801547-16-9 | | MF: | C52H65N7O11S3 | | MW: | 1060.31 | | EINECS: | | | Product Categories: | | | Mol File: | 1801547-16-9.mol |  |
| | PROTAC RIPK degrader-2 Chemical Properties |
| Boiling point | 1196.5±65.0 °C(Predicted) | | density | 1.315±0.06 g/cm3(Predicted) | | pka | 13.54±0.46(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | PROTAC RIPK degrader-2 Usage And Synthesis |
| Uses | PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes[1][2]. | | IC 50 | RIPK2; VHL | | References | [1] Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015 Aug;11(8):611-7. DOI:10.1038/nchembio.1858
[2] Wang C, et al. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem. 2022 Jan 5;227:113906. DOI:10.1016/j.ejmech.2021.113906 |
| | PROTAC RIPK degrader-2 Preparation Products And Raw materials |
|